Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Milestone Pharmaceuticals (MIST – Research Report). The associated price target remains the same with $9.00.
Ritu Baral has given her Buy rating due to a combination of factors surrounding Milestone Pharmaceuticals’ strategic plans and financial positioning. The company’s lead product, etripamil, has a scheduled PDUFA date in March 2025, and upon potential approval, Milestone is poised to receive substantial royalty financing. This potential approval is expected to drive a significant commercial launch, supported by a planned expansion of their sales force to effectively target high-prescribing healthcare professionals.
Furthermore, Milestone’s financial health appears robust, with sufficient cash reserves projected to fund operations through 2026, including the anticipated launch of etripamil. The company’s strategic pricing and distribution plans aim to ensure broad access to etripamil, which could enhance its market penetration. These elements collectively contribute to Ritu Baral’s optimistic outlook and Buy rating for Milestone Pharmaceuticals.
According to TipRanks, Baral is a 5-star analyst with an average return of 8.1% and a 44.60% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Alnylam Pharma, and Sarepta Therapeutics.
In another report released on February 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.